BRPI0508382A - métodos e composições para tratamento de doenças auto-imunes - Google Patents

métodos e composições para tratamento de doenças auto-imunes

Info

Publication number
BRPI0508382A
BRPI0508382A BRPI0508382-6A BRPI0508382A BRPI0508382A BR PI0508382 A BRPI0508382 A BR PI0508382A BR PI0508382 A BRPI0508382 A BR PI0508382A BR PI0508382 A BRPI0508382 A BR PI0508382A
Authority
BR
Brazil
Prior art keywords
compositions
autoimmune diseases
methods
treating autoimmune
copolymers
Prior art date
Application number
BRPI0508382-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Kai W Wucherpfennig
James Rasmussen
Bei Yu
Eric Zanelli
Jack L Strominger
Original Assignee
Peptimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptimmune Inc filed Critical Peptimmune Inc
Publication of BRPI0508382A publication Critical patent/BRPI0508382A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
BRPI0508382-6A 2004-03-01 2005-03-01 métodos e composições para tratamento de doenças auto-imunes BRPI0508382A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54940904P 2004-03-01 2004-03-01
US55139604P 2004-03-09 2004-03-09
PCT/US2005/006822 WO2005085323A2 (en) 2004-03-01 2005-03-01 Methods and compositions for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
BRPI0508382A true BRPI0508382A (pt) 2007-07-31

Family

ID=34922714

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508382-6A BRPI0508382A (pt) 2004-03-01 2005-03-01 métodos e composições para tratamento de doenças auto-imunes

Country Status (13)

Country Link
US (1) US20080194462A1 (https=)
EP (1) EP1725603A2 (https=)
JP (2) JP2007527873A (https=)
KR (1) KR20060125916A (https=)
AU (1) AU2005219876A1 (https=)
BR (1) BRPI0508382A (https=)
CA (1) CA2558655A1 (https=)
IL (1) IL177849A0 (https=)
MX (1) MXPA06010043A (https=)
NO (1) NO20064389L (https=)
NZ (1) NZ549731A (https=)
RU (1) RU2006134701A (https=)
WO (1) WO2005085323A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
ES2565035T3 (es) 2006-04-28 2016-03-30 Momenta Pharmaceuticals, Inc. Métodos para evaluar mezclas de péptidos
WO2008110206A1 (en) * 2007-03-13 2008-09-18 Genome Diagnostics B.V. Method for determining a hla-dq haplotype in a subject
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
WO2010141883A1 (en) * 2009-06-04 2010-12-09 The Regents Of The University Of Colorado Compounds that modulate autoimmunity and methods of using the same
WO2011011706A2 (en) * 2009-07-24 2011-01-27 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2012143924A1 (en) * 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US9629848B2 (en) 2011-05-26 2017-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
WO2014018763A2 (en) * 2012-07-25 2014-01-30 University Of Cincinnati Method of treating type i diabetes using apolipoprotein aiv
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
WO2017165508A1 (en) * 2016-03-24 2017-09-28 Im Therapeutics Methods of treating autoimmune disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
WO2020122609A1 (ko) * 2018-12-11 2020-06-18 주식회사 인트론바이오테크놀로지 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물
EP3899039A4 (en) * 2018-12-20 2022-09-14 The Johns Hopkins University TREATMENT OF TYPE 1 DIABETES, AND OTHER AUTOIMMUNE DISEASES
KR20240091046A (ko) * 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
WO2021026175A1 (en) * 2019-08-05 2021-02-11 Icahn School Of Medicine At Mount Sinai Peptides that block presentation of antigenic islet peptides by hla-dq8 and methods for treating type-1 diabetes
CN120923775B (zh) * 2025-10-13 2026-04-17 浙江大学 一种含有甘氨酸残基和脯氨酸残基的无规共聚物及其合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
DK2239269T3 (da) * 1998-09-25 2013-04-29 Yeda Res & Dev Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
EP1188433B1 (en) * 2000-09-14 2007-01-03 Firmenich Sa Use of unsaturated esters as perfuming ingredients
DE02800437T1 (de) * 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren
JP5495490B2 (ja) * 2004-05-07 2014-05-21 アレス トレーディング エスエイ ランダム共重合体を用いる疾患の治療方法
WO2006031727A2 (en) * 2004-09-13 2006-03-23 President And Fellows Of Harvard College Peptides for treatment of autoimmune diseases

Also Published As

Publication number Publication date
WO2005085323A2 (en) 2005-09-15
US20080194462A1 (en) 2008-08-14
AU2005219876A1 (en) 2005-09-15
KR20060125916A (ko) 2006-12-06
WO2005085323A3 (en) 2007-02-15
NZ549731A (en) 2009-11-27
MXPA06010043A (es) 2007-03-07
IL177849A0 (en) 2006-12-31
JP2007527873A (ja) 2007-10-04
NO20064389L (no) 2006-12-01
EP1725603A2 (en) 2006-11-29
RU2006134701A (ru) 2008-04-10
JP2012001547A (ja) 2012-01-05
CA2558655A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
BRPI0508382A (pt) métodos e composições para tratamento de doenças auto-imunes
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BRPI0513078B8 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
BR112015008311A2 (pt) conjugados fármaco-proteína
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
CO6230997A2 (es) Proteinas de union a antigeno contra proproteina convertasa subtilisina/kexina tipo 9 (pcsk9)
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
BRPI0413466A (pt) anticorpos igf-1r humanos modificados
BRPI0914319B8 (pt) imunoligante que se liga especificamente ao tnf alfa humano e composição
BRPI0509366A (pt) método para remover potássio de um indivìduo animal, formulação farmacêutica, métodos para tratar uma doença e para determinar uma permeabilidade de casca a um ìon, composição farmacêutica, composição de núcleo-casca,e, método para sintetizar um polìmero de alfa-fluroacrilato
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
MX2019008434A (es) Muteínas de lipocalina con afinidad de unión por lag-3.
BR112022000855A2 (pt) Moduladores de nlrp3
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
Hummig et al. Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain.
CO2022014499A2 (es) Moduladores de nlrp3
BR112017010832A2 (pt) composições de aminoácido para o tratamento de sintomas de doença
BR112016007592A2 (pt) proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr
BR112021014566A2 (pt) Moduladores de gpr35
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.